Metformin vs inositol for PMOS, previously called PCOS: the tradeoffs, not the tribalism
Most content treats metformin and inositol like identity badges. They're tools. Here's the evidence on what each actually does, and how to choose based on your goal.
- Metformin has greater efficacy than inositol per the 2023 international guideline.
- Metformin wins for: glucose, hirsutism, central adiposity.
- Inositol may suit: people who want lower side effects and are tracking metabolic markers.
- Letrozole, not either of these, is first-line for anovulatory infertility.
- The decision changes by goal - there is no universal "winner."
The one-paragraph answer
The short answer: If your goal is metabolic outcomes - fasting glucose, insulin sensitivity, hirsutism, central adiposity - metformin has greater efficacy than inositol per the 2023 international guideline. If your goal is "something gentler" and you can accept weaker clinical certainty, inositol may still be a reasonable trial. If your goal is fertility (specifically ovulation induction), letrozole sits ahead of both. The decision is not metformin vs inositol in the abstract. It's about which outcome matters most.
Per the 2023 International Evidence-Based PMOS Guideline.
When metformin has the stronger case
The short answer: Metformin is recommended primarily for metabolic features and has greater efficacy than inositol for hirsutism and waist-to-hip ratio, per the 2023 guideline.1 If you're prioritizing metabolic outcomes, metformin is the evidence-stronger first move.
Specifically, metformin tends to show benefit on:
Glucose regulation - fasting glucose and insulin sensitivity. Hirsutism - visible androgen-related hair growth. Central adiposity - measured as waist-hip ratio. Reduced progression - for those with prediabetes, metformin has long-term outcomes data inositol doesn't have.
Metformin is also accessible. It's generic, decades-old, well-understood by primary care, and inexpensive in most countries. That accessibility is a real factor in treatment decisions, even though no clinical guideline puts it that way.
When inositol still has a real role
The short answer: When metformin side effects are intolerable (mostly gastrointestinal) and the goal is metabolic improvement plus quality-of-life, inositol can be a reasonable swap. The trade is clearer evidence for less side-effect burden. For some people, that trade is the right one.
Inositol may also be the more reasonable opening when:
Metabolic markers are mildly off rather than significantly impaired. You've tried metformin and the side effects were unmanageable. You're tracking specific outcomes - like cycle regularity over a 12-week window - and willing to swap for stronger evidence if inositol doesn't move them.
What inositol is not is "metformin lite." That framing oversells it. Per the guideline summary: inositol "could be considered" but with the explicit caveat that clinical benefits remain limited.1
The side-by-side
A clean comparison helps when the marketing noise gets loud:
Both have a role. The right one depends on your goal and your tolerance.
The bottom line
What we know: Metformin has greater efficacy than inositol for the metabolic features and hirsutism the 2023 PMOS guideline specifically addresses. Both are options. Each has trade-offs. Letrozole is first-line if the goal is fertility.
What we don't know yet: Whether combining metformin with inositol provides additive benefit - early signals suggest it might for some outcomes, but the evidence base is small. Whether different PMOS phenotypes respond differently to each.
What to do next: Name your outcome before you choose your treatment. Bring the right goal to your clinician - metabolic, fertility, cycle regularity, hirsutism - and let the goal determine the order of options. Not the marketing.
References
- Teede HJ et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023. [Link]
- Greff D et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. Monash University. 2023.
- American Society for Reproductive Medicine. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS. [Link]
- Teede HJ et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome. The Lancet. 2026.